Reduced glucose metabolism always accompanies Alzheimer's disease (AD) and the decline is highly correlated with the decline in cognition. Promotion of AD pathology by manipulation of glucose/oxygen utilization in pre-clinical models supports the possibility that these deficits are not mere consequences of the disease, but promote the disease and are potential therapeutic targets. An understanding of the underlying basis for the decline in glucose utilization and its consequences are required to therapeutically target glucose utilization. The decline in mental function before AD patients die is highly correlated to changes in the activities of enzymes related to the mitochondrial tricarboxylic acid (TCA) cycle including the entry level enzyme- the pyruvate dehydrogenase complex (PDHC) and the rate controlling step-?-ketoglutrate dehydrogenase (KGDHC. The proposed studies will test the overall hypothesis that the changes in the TCA cycle underlie the abnormal metabolism and pathology in AD and that reversing them or the downstream consequences will benefit AD patients. We propose that determining the post-translational modifications that diminish the activity of KGDHC in brains from AD patients will reveal the cause of the modification and suggest effective ways to reverse the deficit. The possibility that KGDHC and PDHC may directly modify other TCA cycle enzymes will be tested. The experiments will test whether diminished KGDHC alters the response to drugs that promote mitogenesis and determine the link between the KGDHC and signals for mitochondrial repair in order to manipulate them to enhance mitochondrial repair. Surprisingly little is known about the response of the genes and proteins of the entire TCA cycle to metabolic perturbations and some ?mitogenic? therapies may diminish activities. Thus, the proposal is to test the response of these enzymes at the level of the gene, activity and protein (including post-translational modifications by acetyl or succinyl groups) to select metabolic perturbations to determine better therapeutic targets. The experiments will test the hypothesis that changes in the mitochondrial TCA cycle and the consequent downstream signaling changes are central to the disease process and provide a therapeutic target that is not responsive to mitogenic therapies. Successful completion of these studies will identify additional mechanisms to reverse the deficits and ameliorate the disease process.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG014930-15A1
Application #
8999505
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2016-04-15
Budget End
2017-03-31
Support Year
15
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Winifred Masterson Burke Med Research Institute
Department
Type
DUNS #
780676131
City
White Plains
State
NY
Country
United States
Zip Code
10605
Tapias, Victor; Jainuddin, Shari; Ahuja, Manuj et al. (2018) Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Hum Mol Genet 27:2874-2892
Garg, Ankur; Hannan, Abdul; Wang, Qian et al. (2018) FGF-induced Pea3 transcription factors program the genetic landscape for cell fate determination. PLoS Genet 14:e1007660
Franich, Nicholas R; Basso, Manuela; André, Emily A et al. (2018) Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models. J Huntingtons Dis 7:137-150
Karuppagounder, Saravanan S; Zhai, Yujia; Chen, Yingxin et al. (2018) The interferon response as a common final pathway for many preconditioning stimuli: unexpected crosstalk between hypoxic adaptation and antiviral defense. Cond Med 1:143-150
Ratan, Rajiv R (2017) Building on NeuroNEXT: Next generation clinics to cure chronic neurological disability. Ann Neurol 82:859-862
Starkov, Anatoly A; Chinopoulos, Christos; Starkova, Natalia N et al. (2017) Divalent cation chelators citrate and EDTA unmask an intrinsic uncoupling pathway in isolated mitochondria. J Bioenerg Biomembr 49:3-11
Chen, Huanlian; Xu, Hui; Potash, Samuel et al. (2017) Mild metabolic perturbations alter succinylation of mitochondrial proteins. J Neurosci Res 95:2244-2252
Shurubor, Yevgeniya I; D'Aurelio, Marilena; Clark-Matott, Joanne et al. (2017) Determination of Coenzyme A and Acetyl-Coenzyme A in Biological Samples Using HPLC with UV Detection. Molecules 22:
Zille, Marietta; Karuppagounder, Saravanan S; Chen, Yingxin et al. (2017) Neuronal Death After Hemorrhagic Stroke In Vitro and In Vivo Shares Features of Ferroptosis and Necroptosis. Stroke 48:1033-1043
Gibson, Gary E; Thakkar, Ankita (2017) Interactions of Mitochondria/Metabolism and Calcium Regulation in Alzheimer's Disease: A Calcinist Point of View. Neurochem Res 42:1636-1648

Showing the most recent 10 out of 195 publications